CD33 CART AML
Contact
Description
This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML). Patients who are between ages 1 to 30 years with relapsed or refractory AML will be eligible for this study.
Eligibility and criteria
IRB Number:
19-016623
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.